Prosperitas Financial LLC Buys 88,922 Shares of Hims & Hers Health, Inc. $HIMS

Prosperitas Financial LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 88,922 shares of the company's stock, valued at approximately $2,649,000.

A number of other institutional investors have also made changes to their positions in HIMS. Versant Capital Management Inc lifted its holdings in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company's stock valued at $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after purchasing an additional 319 shares during the period. GK Wealth Management LLC acquired a new position in shares of Hims & Hers Health in the third quarter valued at $37,000. Compass Financial Management LLC acquired a new position in shares of Hims & Hers Health in the second quarter valued at $50,000. Finally, Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 180.7% in the first quarter. Bogart Wealth LLC now owns 2,526 shares of the company's stock valued at $52,000 after purchasing an additional 1,626 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: U.S. Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The policy could improve Hims & Hers’ access to compounded treatments and support growth, although its temporary nature creates continuing uncertainty. Hims & Hers Jumped as HHS Uses Enforcement Discretion to Open Peptide Compounding
• Positive Sentiment: Earlier strength in telehealth stocks following Teladoc’s better-than-expected results provided some support for Hims & Hers and highlighted continued investor interest in digital-health companies. Teladoc Soars as Revenue and Profit Beat Estimates
• Neutral Sentiment: Insider Soleil Boughton sold 3,462 shares for approximately $95,551 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s position by about 1.16% and is therefore a limited signal about management’s outlook. SEC Insider Trading Filing
• Negative Sentiment: Multiple law firms are soliciting investors ahead of the November 2, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases from August 4, 2025, through July 29, 2026. The litigation stems in part from allegations associated with an FTC complaint and could expose Hims & Hers to legal expenses, potential damages, reputational harm and further scrutiny. The repeated notices appear to be the primary near-term catalyst weighing on the stock. HIMS Securities Class Action Deadline Alert

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 3,462 shares of the firm's stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $27.60, for a total value of $95,551.20. Following the transaction, the insider owned 293,886 shares in the company, valued at approximately $8,111,253.60. This trade represents a 1.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of the business's stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the completion of the transaction, the chief financial officer directly owned 234,527 shares of the company's stock, valued at approximately $6,965,451.90. This trade represents a 0.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 133,905 shares of company stock valued at $3,826,977. 11.76% of the stock is owned by corporate insiders.

Hims & Hers Health Trading Down 7.0%

Shares of HIMS stock opened at $27.59 on Friday. The stock has a market cap of $6.44 billion, a P/E ratio of -43.79 and a beta of 2.44. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $48.34. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The stock has a 50 day simple moving average of $29.04 and a 200 day simple moving average of $27.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%. Hims & Hers Health's revenue was up 38.2% on a year-over-year basis. During the same quarter last year, the business earned $0.17 EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HIMS. Truist Financial raised their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a research note on Monday, August 24th. Citigroup decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a "hold" rating in a research note on Tuesday, August 11th. Bank of America increased their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.